STOK's Quality Score fell 1 point on Tue, Nov 10, to -2. Buying slipped from its highest in 20 days (2 chart checks stopped).
Follow STOK's trial news. Pro members can get an alert when Stoke Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 512% over three years while the S&P 500 rose 80%.
| Holding it back | Sales down 86% on the year |
| Latest filing | 10-Q, Nov 3 |
Tue Nov 10: Guggenheim 3rd Annual Global…Investor conference · date confirmed.
1 more date ahead: the conference, for Pro members.
After its last 4 reports it closed -0.8% on average, higher 2 of 4 times.
About 6 quarters
Chief Medical Officer Barry Ticho sold 7,195 shares on Nov 2, under a planned sale. 21 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Poorfor quality, not price, 4 of 14 chart checks firingWhat the Quality Score means
STOK is #165 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 165 |
Expected to report Mon Mar 15, after the close (in 125 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $11.3M, 6% more than a year ago; a loss of $1.08 a share, from $0.65.
“The decrease in revenue is primarily driven by the recognition of $150.8 million related to the Biogen IP license performance obligation during the nine months ended September 30, 2025.”
STOK's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“The increase was driven by increased activities and personnel expenses to support the advancement of zorevunersen.”
From its results filing (SEC filing · Oct 29)
Its share count grew 15% a year over 3 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Oct 29, 2026 | -1.2% | -0.2% | -1.1% |
| Aug 3, 2026 | -2.6% | +7.1% | +9.0% |
| May 7, 2026 | -2.6% | +0.3% | -4.4% |
| Jan 12, 2026 | -16.6% | -10.4% | -12.6% |
Sales grew in two of the last three years, to $184M in 2025. It lost money in each of the four years.
RSI 55.3, MACD above signal, above its 50-day, below its 200-day. Not scored.
3 insiders sold $647K across 6 filings in the last 6 months. No open-market buys on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: STOK is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
“The biotechnology and biopharmaceutical industries, and the genetic medicines fields, are characterized by rapid evolution of technologies, fierce competition and strong defense of intellectual property.”
STOK scores -2 today, which Breakaway calls Poor. It is #165 of 281 in Biotech by Quality Score, with 4 of 14 chart checks firing. Up 512% over three years while the S&P 500 rose 80%. Cash lasts about 6 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
STOK scores -2 today, which Breakaway calls Poor (below zero). That is #165 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind STOK's -2.
3 insiders sold $647K across 6 filings in the last 6 months. No open-market buys on record. The newest is Edward M. Kaye, Director, who sold $382K on Aug 18. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.